PML-RARα and p21 are key factors for maintaining acute promyelocytic leukemia stem cells survival.
- Author:
Fei DING
1
;
Jun-Min LI
Author Information
1. Department of Hematology, Shanghai Jiaotong University School of Medicine, Shanghai, China.
- Publication Type:Journal Article
- MeSH:
Cell Survival;
Cyclin-Dependent Kinase Inhibitor p21;
Humans;
Leukemia, Promyelocytic, Acute;
metabolism;
pathology;
Neoplastic Stem Cells;
cytology;
Oncogene Proteins, Fusion;
Signal Transduction;
Tumor Cells, Cultured
- From:
Journal of Experimental Hematology
2011;19(5):1299-1302
- CountryChina
- Language:Chinese
-
Abstract:
Tumor stem/progenitor cells are the cells with the characteristics of self-renewal, differentiating to all the other cell populations within tumor, which are also regarded as the source of tumor relapse, drug-resistance and metastasis. As a subtype of acute myeloid leukemia, acute promyelocytic leukemia (APL) represents the target of therapy due to the good response of the oncogenic protein PML-RARα to all-trans retinoic acid (ATRA) and arsenic trioxide (ATO). This review summarizes the latest research results of APL as follows: (1) there probably are two APL stem/progenitor cell populations within APL, and self-renewal and survival of APL stem/progenitor cells highly depend on PML-RARα expression, cell cycle inhibitor p21, self-renewal associated molecules and chemokines; and (2) ATRA and ATO eradicate APL stem/progenitor cells mainly by PML-RARα degradation, FOXO3A activation and the inhibition of self-renewal-associated signaling pathway of sonic hedgehog. These findings are helpful to improve other tumor therapy.
